Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France

Condition(s) studied

Investigational drug(s) / intervention(s)

ribociclib + ET: There is no treatment allocation. Patients administered ribociclib + endocrine Therapy (ET) by prescription will be enrolled.

Study summary

This study is a national, multicenter, prospective, non-interventional study in women with HR+/HER2- locally advanced or metastatic breast cancer (BC), for which a prior clinical decision to initiate ribociclib + endocrine therapy (ET) treatment according to the marketing authorization has been taken and was taken independent and prior to study participation decision.

Eligibility

Primary outcome measure(s)

• Proportion of patients by initial dose of ribociclib — Baseline
  Proportion of patients by initial dose of ribociclib to be collected
• Proportion of patients by endocrine therapy partner — Baseline, up to 54 months
  Proportion of patients by endocrine therapy partner to be collected(e.g., tamoxifen, letrozole, fulvestrant, anastrozole, exemestane, LHRH agonist)
• Proportion of patients for each line of treatment with ribociclib — Baseline
  Proportion of patients for each line of treatment with ribociclib (1L, 2L, \>2L) to be collected

Trial sites (82)

+ 42 more sites — see the full list on the official registry below.

More Novartis Pharmaceuticals trials in France

Other trials for the same condition